April 4, 2025
Orthocell (ASX:OCC) cleared for take-off in the US nerve repair market
Orthocell’s FDA clearance for its Remplir™ nerve repair device marks a major commercial milestone, unlocking access to the US$1.6 billion US market and positioning the Perth-based company for global growth and profitability.
